Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line

Giacomo Miserocchi, Alessandro De Vita, Laura Mercatali, Federica Recine, Chiara Liverani, Chiara Spadazzi, Federica Pieri, Nada Riva, Alberto Bongiovanni, Roberto Casadei, Valentina Fausti, Toni Ibrahim

Research output: Contribution to journalArticle

Abstract

Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient's tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient's tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.

Original languageEnglish
JournalCells
Volume7
Issue number11
DOIs
Publication statusPublished - Oct 25 2018

    Fingerprint

Cite this